<DOC>
	<DOCNO>NCT02339415</DOCNO>
	<brief_summary>The purpose study evaluate effect pharmacologic FXa inhibition ( via edoxaban 30 mg daily ) inflammation , reflect plasma Interleukin-6 level .</brief_summary>
	<brief_title>Targeted Anticoagulation Therapy Reduce Inflammation Cellular Activation Long-term HIV Disease</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Inclusion Criteria HIV infection ( verified previous positive antibody detectable HIV RNA level ) Age ≥18 year Receiving continuous ART ≥2 year ( regimen change &gt; 3 month prior enrollment acceptable ) HIV RNA level ≤200 copies/mL ≥1 year ( 1 measure ≥200 allow also &lt; 500 precede follow one value ≤200 copies/mL ) Ddimer level ≥100 mg/L ( ng/mL ) screening ( within prior month ) Estimated creatinine clearance ≥50 mL/min Body weight ≥60kg Do anticipate starting ( stop ) statin aspirin therapy study For woman child bear potential , agree use reliable form birth control Exclusion Criteria Pregnancy breast feed A contraindication take edoxaban A clinical indication anticoagulation therapy ( e.g. , atrial fibrillation Deep Vein Thrombosis/PE ) Treatment antiplatelet , anticoagulation , immunemodulatory drug currently within past 6 month ; prior selflimited treatment aspirin ( i.e. , daily use ) exclusion . Grade ≥1 hematology lab abnormality INR ( &gt; 1.1 x ULN ) , hemoglobin ( &lt; 10.0 g/L ) , platelet ( &lt; 100,000 cells/μL ) , WBC ( 2,500 cells/mm3 ) Grade ≥2 lab abnormality chemistry ( BMP ) liver panel Alcohol illicit drug abuse/dependency within prior year History prior myocardial infarction unstable atherosclerotic disease History prior stroke transient ischemic attack ( TIA ) History active gastrointestinal ulcer bleed disorder within prior year Intent surgery study period ( 12 month ) Hepatitis C treatment ( e.g. , interferon , ribavirin , protease inhibitor ) within past 6 month Cirrhosis hepatic impairment ( e.g. , ChildPugh class B C ) . Seizure disorder Previous/current CNS space occupy lesion ( e.g. , Toxoplasmosis , mTB ) persistent abnormality CNS image completion treatment . Surgical invasive procedure anticipate study period . Invasive cancer prior year receive cancer treatment ( include carcinomainsitu basal cell cancer skin ) Rheumatologic inflammatory disease , systemic nature ( e.g. , systemic lupus erythematosus , rheumatoid arthritis , vasculitis , sarcoidosis , Crohn 's disease ) Assessment clinical investigator enrollment study could entail excess risk participant , beyond intend expect .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>